Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

CML therapy for patients on dialysis

  • Jeff Lipton
  • Jeff Lipton's Avatar Topic Author
8 years 11 months ago #1030 by Jeff Lipton
CML therapy for patients on dialysis was created by Jeff Lipton
Received from a colleague of mine. Patient is a 42 year-old man referred with leukocytosis (WBC 42, mostly neutrophils and myeloids; 0 - 2% circulating blasts); molecular is positive for BCR-ABL1 (p210). Bone marrow pending.

The complicating factor in this man is that he has had both his kidneys removed, as well as his bladder for multiply-recurrent transitional cell CA. He is 4 years out from completing treatment and is on nocturnal home dialysis, getting around 30 - 40 hours of dialysis per week. His GFR is less than 10 (obviously).

He has no other major co-morbidities, and his meds include darbepoietin, pantoprazole, and citalopram.

Questions:

1) What TKI would you suggest using?


2) Are dose adjustments to the TKIs needed?
  • Devendra Hiwase
  • Devendra Hiwase's Avatar Topic Author
8 years 11 months ago #1031 by Devendra Hiwase
Replied by Devendra Hiwase on topic CML therapy for patients on dialysis
Regarding dasatinib, imatinib and nilotinib with dialysis;

There is limited information on use of these drugs in renal impairment or with dialysis, so they should be used with caution - but overall it is thought that they are unlikely to be dialysed.
See further information below:

Dasatinib
• Mainly hepatic metabolism
• Minimal urinary excretion, <4% renally excreted
o Unlikely to be dialysed  dose as in normal renal function
• Note, may cause fluid retention
o Monitor patient closely

Imatinib
• Mostly hepatic metabolism
• Some urinary excretion, ~13% renally cleared (drug and metabolites)
o Unlikely to be dialysed  some references suggest can dose as in normal renal function, while others suggest to start with a reduced dose and monitor closely (one reported that a dose 100mg daily was tolerated in a limited number of patients with severe renal impairment, while the product information suggests that 400mg may be a suitable starting dose)
• Note fluid retention/oedema very common – monitor closely
o Higher probability if higher doses, age>65, Hx cardiac disease
• Also may rarely cause severe elevation of serum creatinine - monitor

Nilotinib
• Mainly hepatic metabolism
• Close to no renal excretion
o Unlikely to be dialysed (no information on this, but dosage adjustments for renal dysfunction unlikely to be necessary)  dose as in normal renal function and monitor closely

References
• Drug Information Handbook for Oncology – 12th edition (American Pharmacist’s Association)
• eMIMS
• eviQ
• Renal Drug Handbook 3rd Edition (Ashley + Currie)
Moderators: Nicolaarlene